New NPS MedicineWise annual evaluation report indicates Australian PBS savings

18 February 2014
canberra-big

The 16th NPS MedicineWise Annual Evaluation Report provides a snapshot of the organization’s progress and key achievements for the 2012-13 financial year, showing its interventions in general practitioners’ prescribing have reduced scripts for high dose statins and dementia drugs, delivering tens of millions in Prescription Benefit Scheme (PBS) savings to the Australian government.

NPS MedicineWise chief executive Lynn Weekes says the report outlines the organization’s success in creating both health and economic impacts. “I’m proud of the good work we have done in the past financial year to enable people to make the best decisions about medicines and other medical choices to achieve better health and economic outcomes,” says Dr Weekes.

The report shows that programs delivered in primary care over the past decade have had considerable health impacts in terms of improving prescribing and cardiovascular management and encouraging adherence to pharmacological treatment among patients with diabetes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical